Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px
Document › Details

Creathor Venture Management GmbH. (6/29/16). "Press Release: A Perfect Match – Caprotec Bioanalytics Collaborates with Charles River".

Organisations Organisation Caprotec Bioanalytics GmbH
  Organisation 2 Charles River (Group)
Product Product CCMS technology (Capture Compound Mass Spectrometry)
Index term Index term Charles River–Caprotec: CCMS technology, 201606 collab use of CCMS tech to identify protein targets relevant for phenotypic drug candidate responses
Persons Person Montana, John (Charles River 201709– VP Integr Drug Discovery/Strategic Projects joined 2014 before Argenta+Paradigm)
  Person 2 Köster, Hubert (Caprotec 200805–201009 Managing Director + Univ Hamburg + Sequenom founder + CEO)
     


The phenotypic-based screening approach to drug discovery is an efficient strategy to identify promising small molecule hits by looking at the effect, or phenotype, that they induce in disease-relevant cells or tissues. One major challenge for progressing hits from phenotypic screens to mature lead compounds is the identification of the protein target or targets that are responsible for the phenotypic effect. Therefore, molecular target identification, also known as target deconvolution, is an essential part of the process for understanding compound mechanism of action and further optimizing compounds of interest.

“Traditional approaches to target deconvolution, such as affinity binding chromatography, are largely decoupled from biological conditions under which screening hits exert phenotypic activity and lack the precision required to differentiate between off-target binding and proteins the compound is targeting selectively”, notes John Montana, Charles River’s Executive Director of Scientific Alliances in Europe. “Another drawback of these techniques is the workflow involved in preparing an affinity binding chromatography assay – because the compound required to interact with the biological material is bound to agarose. Therefore, the utility to identify cell surface and intracellular proteins, such as G-protein coupled receptors, kinases and epigenetic targets, is severely compromised”.

New advances in combining linker and capture technologies with in-depth knowledge of how these are attached to phenotypic molecules of interest, combined with powerful LC-MS techniques such as the Capture Compound Mass Spectrometry (CCMS) technology developed by and proprietary to caprotec bioanalytics, GmbH, enables scientists to overcome these obstacles and better identify target proteins that are responsible for the phenotypic response. CCMS technology uses trifunctional molecules, combining reversible affinity binding and cross-linked-induced covalent binding, to selectively bind, capture, isolate and identify compound targets. This, at unprecedented sensitivity, allows for the isolation and identification even of low abundant specific binders of drug candidates under the conditions of the relevant phenotypic assays, thus correlating specific binders with biological activity and target engagement. Uniquely, CCMS permits the specific capture of proteins from any target class from living cells.

As a result of Charles River’s continued commitment to emerging drug discovery technologies, a strategic collaboration has been established with caprotec bioanalytics, GmbH, to offer their proprietary protein capture technology for phenotypic screening target deconvolution. Prof. Hubert Köster, Founder and CEO of caprotec, notes: “We’re looking forward to working with Charles River. Our CCMS technology is complementary to their strong track record in phenotypic screening.” John Montana adds, “Both caprotec and Charles River are driven to helping pharmaceutical and biotech companies accelerate the development of better, safer products, and I’m confident this partnership will be able to advance that mission for both companies.”

   
Record changed: 2018-02-11

Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px